The filing confirms a severe liquidity crisis. The company's survival hinges on the post-period US$3.5M debt financing (May 2026) and continued ELOC share sales. Monitor for any going-concern qualification in the next 20-F or further dilutive financing announcements. The stock is likely to face continued pressure given the cash runway is effectively zero without external support.
Price Chart
Executive Summary
Gelteq's 6-K filing for H1 FY2026 reveals a critical liquidity crisis: cash and cash equivalents collapsed to just AUD $9,349 (down 97% from AUD $344,648 at June 30, 2025), while the net loss widened to AUD $3,742,104 and the working capital deficit reached AUD $5,338,422. The pre-revenue biotech has no revenue from contracts with customers and is entirely dependent on external financing—including a post-period US$3.5M debt facility and an ELOC—to continue operations.
Key Facts
- Cash and cash equivalents fell to AUD $9,349 as of December 31, 2025, from AUD $344,648 at June 30, 2025
- Net loss widened to AUD $3,742,104 for H1 FY2026 from AUD $3,304,359 in H1 FY2025
- Working capital deficit of AUD $5,338,422 (current liabilities exceed current assets)
- Zero revenue from contracts with customers for both H1 FY2026 and H1 FY2025
- Total borrowings of AUD $5,113,954, of which AUD $5,100,404 is classified as current
- Accumulated losses reached AUD $21,883,487
Financial Impact
Cash burn rate of approximately AUD $180,000 per month (based on operating cash outflow of AUD $1,082,688 over six months), with only AUD $9,349 in cash remaining as of December 31, 2025
Risk Factors
- Going concern risk if additional financing is not secured
- Severe dilution from convertible notes, ELOC, and the new debt facility
- Failure to achieve commercial revenue or clinical milestones
- Default on current borrowings (AUD $5.1M current) if not extended or refinanced
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-073846 |
| Document: ea029599601ex99-1.htm | 0001213900-26-073846 |
| Document: ea0295996-6k_gelteq.htm | 0001213900-26-073846 |
| Document: 0001213900-26-073846-index-headers.html | 0001213900-26-073846 |
| Document: 0001213900-26-073846-index.html | 0001213900-26-073846 |
| Document: 0001213900-26-073846.txt | 0001213900-26-073846 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 30, 2026 16w ago | 6-K | $0.6600 $0.5500 | ▲ +16.67% | ▲ +19.54% | $0.4470 (+32.27%) |
Jun 17, 2026 18w ago | Press Release | $1.14 $0.7001 | ▼ −38.59% | ▼ −41.74% | $0.4470 (−60.79%) |
Jun 12, 2026 19w ago | Press Release | $0.9900 $0.6762 | ▼ −31.70% | ▼ −34.96% | $0.4470 (−54.85%) |
Jun 2, 2026 20w ago | 6-K | $0.4860 $0.5701 | ▼ −17.30% | ▼ −14.81% | $0.4470 (+8.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers